FutureMeds and the Oncological Movement Association PARS join forces to increase access to oncology trials
- FutureMeds
- Mar 17
- 4 min read
FutureMeds and the Oncological Movement Association PARS join forces to increase cancer awareness and provide patients with easy access to new therapeutic options via clinical trials
Cancer cases are expected to rise significantly through 2050, particularly in lower-income countries, potentially increasing by more than 12 million new cases annually to 32 million.
To bring novel therapies to patients faster, global spending on cancer medicine is projected to increase by 83% and reach $409 billion by 2028. However, the pace of bringing novel therapies to patients is uneven.
Patient access is impacted by factors such as differences in biomarker testing rates, adoption of novel therapies and infrastructure capacity to deliver some of the most advanced therapies.
Progress in this field hinges upon funding for therapeutic innovations, drug discovery, and clinical research and cooperation between pharmaceutical companies, research sites, researchers and patients. More than 2,000 new oncology clinical trials started in 2023 with novel modalities and significant promise for cancer treatment, including cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies. However, patient participation in oncology trials hasn’t significantly increased for decades.
It is for the latter reason that FutureMeds and the Oncological Movement Association PARS decided to take joint action. The shared goal is to increase access to clinical trials for oncology patients.
"Many patients do not realise how important clinical trials are in oncology. We want to change that. Our cooperation with PARS opens up new possibilities for patients, giving them a real chance for free and safe access to innovative therapies."
— Dr Piotr Rozpondek, Managing Director of FutureMeds Poland
Founded by Elżbieta Kozik and formerly known as the Polish Amazons Social Movement, the PARS Oncological Movement is dedicated to all cancer patients and their loved ones.
“The cooperation between our organizations is a step towards a new era in cancer treatment – providing patients with reliable information about the latest therapeutic options and enabling them to participate in innovative medical programs.”
— Elżbieta Kozik, President of the Oncological Movement Association PARS
Key Campaign Focus: Breast Cancer, Melanoma and Lung Cancer
To drive progress and reach both organisations' shared goal of providing easy access to new therapeutic options for cancer patients, the joint awareness campaign will focus on topics such as Breast Cancer, Melanoma and Lung Cancer.
In these areas, FutureMeds' dedicated research sites in Krakow and Wroclaw are already offering patients trial opportunities or implementing trials with the aim of providing more effective treatment methods and improving the quality of life of patients through access to modern therapies and innovative medical solutions.
FutureMeds is currently implementing the following projects:
clinical trials for patients with metastatic or advanced HER2-low breast cancer at FuturMeds Wrocław
Clinical trials in skin melanoma and small cell lung cancer at FutureMeds Krakow.
How patients, doctors and specialists will benefit
By combining the knowledge, experience and reach of FutureMeds and PARS:
Oncology patients will receive current information about the latest clinical trials and treatment options,
Doctors and specialists will have access to innovative therapies that could become the future of medicine,
Together, we will build awareness of the importance of clinical trials and their impact on the development of modern oncology.
"Our priority is to reach patients who need it most with information about clinical trials. Thanks to our cooperation with PARS, we can more effectively inform cancer patients about innovative treatment methods and educate them about clinical trials, which are so important in the fight for a better tomorrow of medicine."
— Arkadiusz Kasperski, Head of Patient Engagement at FutureMeds Poland
Through the planned educational campaign, our shared aim is to keep oncology patients up to date on ongoing and new clinical research projects at FutureMeds facilities.
Every interested patient will gain access to a dedicated hotline, they can call to receive detailed information on ongoing research projects. FutureMeds will also provide the possibility of free oncology consultations aimed at educating and introducing specific clinical trials to initially interested patients.
About PARS Oncological Movement
Founded by Elżbieta Kozik and formerly known as the Polish Amazons Social Movement, the PARS Oncological Movement has been tirelessly supporting people affected by cancer and their loved ones at every stage of treatment since 2009, offering them education, assistance and access to modern treatment methods.
The PARS Oncological Movement
Helps you cope with cancer at every stage of treatment and recovery.
Provides advice on how to navigate the oncology care system and how and where to obtain the necessary information.
Guides you step by step through all phases of cancer treatment.
Strengthens patients and their loved ones in coping with the stress resulting from diagnosis.
Conducts educational, assistance and support activities for many patients and their families.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.
Kommentare